Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients.
Flaminia OlearoIlona KronigStavroula Masouridi-LevratYves ChalandonNina KhannaJakob PasswegMichael MedingerNicolas J MuellerUrs SchanzChristian Van DeldenDionysios NeofytosPublished in: Open forum infectious diseases (2020)
In a large, multicenter, contemporary, 8-year, cohort study, one third of allogeneic-hematopoietic cell transplant (HCT) recipients with Pseudomonas aeruginosa (PSA) infection developed a recurrent infection within 3 months. Antibiotic treatment duration of ≥14 days was the only significantly associated variable with reduced recurrence rates of PSA infections in allogeneic-HCT recipients.
Keyphrases
- pseudomonas aeruginosa
- bone marrow
- stem cell transplantation
- prostate cancer
- cystic fibrosis
- single cell
- cell therapy
- stem cells
- high dose
- mesenchymal stem cells
- biofilm formation
- clinical trial
- acinetobacter baumannii
- combination therapy
- radical prostatectomy
- staphylococcus aureus
- cell proliferation
- signaling pathway
- cell death
- drug resistant